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Abstract 
 
Background: Whether abnormal myocardial perfusion scintigraphy (MPS), dobutamine stress 
echocardiography (DSE) or coronary angiography, performed during preoperative evaluation for 
potential kidney transplant recipients, predicts future cardiovascular morbidity is unclear. We 
assessed test performance for predicting all-cause mortality, cardiovascular mortality and major 
adverse cardiac events (MACE).  
Methods: We searched MEDLINE and EMBASE (to February 2014), appraised studies and 
calculated risk differences (RD) and relative risk ratios (RRR) with 95% confidence intervals using 
random effects meta-analysis.  
Results: 52 studies (7401 participants) contributed data to the meta-analysis. Among the different 
tests, similar numbers of patients experienced MACE after an abnormal test result compared with a 
normal result (RD: MPS 20 per 100 patients tested (95% CI: 0.11–0.29), DSE 24 (95% CI: 0.10–
0.38) and coronary angiography 20 (95% CI: 0.08–0.32; P=0.91). Although there was some 
evidence that coronary angiography was better at predicting all-cause mortality than MPS (RRR 
0.69, 95% CI: 0.49–0.96; P=0.03) and DSE (RRR 0.72, 95% CI: 0.50, 1.02; P=0.06), non-invasive 
tests were as good as coronary angiography at predicting cardiovascular mortality (RRR MPS 0.89, 
95% CI: 0.38–2.10; P=0.78; DSE 1.09, 95% CI: 0.12–10.05; P=0.93) and MACE (RRR MPS 1.09, 
95% CI: 0.64–1.86; P=0.74; DSE 1.56, 95% CI: 0.71–3.45; P=0.25). 
Conclusions: Non-invasive tests are as good as coronary angiography at predicting future adverse 
cardiovascular events in advanced chronic kidney disease. However, a substantial number of people 
with negative test results go on to experience adverse cardiac events. 
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Introduction 
 
Cardiovascular evaluation is an important part of the preoperative workup of potential kidney 
transplant candidates. Cardiac tests aim to identify patients at increased risk of future major adverse 
cardiovascular events (MACE) who may benefit from pre-emptive medical or surgical intervention 
prior to receiving a transplant. The scarcity of organs available for transplant means that 
cardiovascular evaluation results inform the best use of a limited resource, by excluding patients 
with unmodifiable advanced cardiovascular disease and poor long term prognosis (1).  
 
While on the transplant waiting list, and after transplantation, cardiovascular disease is the 
commonest cause of death. Recent systematic reviews of diagnostic test accuracy have 
demonstrated that non-invasive functional tests have moderate accuracy in predicting obstructive 
coronary artery disease in potential kidney transplant recipients (2,3). Non-invasive cardiac tests 
(e.g. myocardial perfusion scintigraphy, MPS, and dobutamine stress echocardiography, DSE) 
perform well in predicting cardiovascular events in the general population undergoing major non-
cardiac surgery (4-8), but their performance in patients with end-stage kidney disease (ESKD) is 
unclear. In patients with ESKD, not all cardiovascular events are caused by myocardial ischaemia, 
with congestive cardiac failure and fatal ventricular arrhythmia being major causes of 
cardiovascular mortality (9). Patients with ESKD also have a high incidence of cardiomyopathy, 
hypertension and calcific coronary artery disease (associated with coronary flow reserve 
abnormalities), all of which may affect cardiac test performance and test results (10-12). Accurately 
identifying patients with obstructive coronary artery disease may not necessarily identify patients 
who are at high risk of MACE following transplantation.  
 
Clinical guidelines from the American Heart Association / American College of Cardiology 
Foundation (13),  American Society of Transplantation (14), Canadian Society of Transplantation 
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(15), and UK Renal Association (16) recommend using a non-invasive test in patients with known 
coronary artery disease, symptoms of coronary artery disease and in asymptomatic individuals with 
multiple risk factors for coronary artery disease.  Coronary angiography is recommended as a 
subsequent test in patients with an abnormal non-invasive testing. These guidelines do not specify 
which non-invasive test should be used, other than that this should be determined by local 
availability and expertise. Despite this guidance, uncertainty among clinicians means clinical 
practice varies in deciding which patients to test and which tests to use when evaluating people for 
kidney transplantation. 
 
We undertook a systematic review to evaluate the prognostic value of cardiac tests in predicting 
future MACE, cardiovascular mortality and all-cause mortality in patients being considered for 
kidney transplantation. 
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Materials and Methods 
 
Search Strategy 
 
Two investigators searched MEDLINE and EMBASE (via OvidSP) from inception to April 30, 
2014 without language restriction, using MeSH headings and text word terms for kidney 
transplantation, chronic kidney disease and index tests (SDC, Materials and Methods). To locate 
studies not indexed in MEDLINE or EMBASE, we included citation tracking through Web of 
Science and checked bibliographies of relevant identified studies. Inter-observer agreement was 
reported using the kappa coefficient. 
 
We included all cohort studies and randomised controlled trials which reported prognostic 
outcomes and tested adult potential kidney transplant recipients. Cardiac tests included MPS, DSE, 
coronary angiography, exercise and resting ECG, electron beam computed tomography, computed 
tomography coronary angiography, cardiovascular magnetic resonance imaging and 
cardiopulmonary exercise testing. We excluded studies of patients who were not candidates for a 
kidney transplant (i.e. unselected dialysis patients not undergoing pre-transplant assessment).  
 
Using a structured template, we extracted details of design, setting, duration, and the outcomes 
reported in each study.  We also recorded which cardiac test was used, the definition of an 
abnormal cardiac test, and baseline characteristics of the study population.  Our outcomes included 
all-cause mortality, cardiovascular mortality, and MACE. The definition of MACE included 
cardiovascular death, myocardial infarction, arrhythmia and pulmonary oedema. MACE only 
included coronary revascularization when it was undertaken following myocardial infarction, or 
arrhythmias caused by myocardial ischaemia. Cardiovascular death included death from 
myocardial infarction, arrhythmia and stroke.   
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Two reviewers independently performed methodological quality assessment of included studies 
using existing guidelines (17,18). Where possible, we contacted study authors to obtain data not 
available in published format. This systematic review of prognostic accuracy is an extension of an 
existing systematic review of diagnostic test accuracy, which had a  published protocol (2). 
 
Quantitative Data Synthesis 
 
We calculated pooled risk difference (RD) and relative risk (RR) of an abnormal test predicting 
each of the pre-specified outcomes, with their 95% confidence intervals (CI) using a random effects 
model (Review Manager 5.1 (www.revman.com) and tested for heterogeneity using the Cochran Q 
statistic and I2 values.  We expressed the risk difference as the number of additional patients (per 
100 patients tested) with an abnormal test result that developed the outcome compared with those 
with a normal test result. For each outcome, we produced summary forest plots stratified by cardiac 
test. We then investigated sources of heterogeneity using subgroup analyses and meta-regression. 
First, we grouped MPS and DSE studies according to their definition of what an abnormal test was.  
Specifically, we investigated whether our results varied among studies which classified patients 
with fixed defects without reversible components as being normal or abnormal. For studies which 
used coronary angiography, we investigated whether the threshold of stenosis used to diagnose 
coronary artery disease (≥50% or ≥70%) changed our results. To investigate confounding by 
multiple study-level characteristics, we then fitted a multivariate-adjusted random-effects meta-
regression model for each cardiovascular outcome using SAS9.2 (www.sas.com). We investigated 
how the likelihood of each outcome varied by which cardiac test was used, the prevalence of 
coronary artery disease and diabetes mellitus, the positive test rate in the study population and the 
duration of follow up. Finally, when data were available, we performed multivariate logistic 
regression to analyse how revascularization or transplantation affected the risk of each pre-
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specified cardiovascular outcome. As treatment strategies, perioperative management of patients 
with cardiovascular risk, transplant age as well as performance of cardiac tests differ over time, and 
since this also has the potential to affect post-test outcomes, we also performed a sensitivity 
analysis including studies which were published from 2000 onwards.  
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Results 
 
Studies Included for Analysis 
 
We included 100 studies (Fig. 1). Outcome data suitable for meta-analysis for individual tests could 
not be extracted from 48 studies (SDC, References), so 52 studies (7401 participants) were 
included in data synthesis.  Inter-observer agreement for data abstraction and bias assessment was 
good (kappa=0.87). Characteristics of included studies are presented in Table 1. One research 
group produced seven studies with overlapping populations (19-25), and so we included only the 
study which had the largest population of patients to avoid bias by including the same participants 
more than once. No studies were found evaluating electron beam computed tomography, computed 
tomography coronary angiography, cardiovascular magnetic resonance imaging and 
cardiopulmonary exercise testing. 
 
The results of the methodology quality assessment are presented in SDC Fig. 1 and SDC Table 1. 
Whether the assessors of outcomes or cardiac test results were blinded to test results was reported 
in only 26 of 52 studies (outcome assessment was blinded in 11 studies, unblinded in 15 studies), 
and unknown in 26 studies. All studies had a population which was representative of the average 
patient with ESKD undergoing pre-transplant cardiac evaluation and used appropriate statistical 
analysis on the outcome data provided.  
 
All-cause Mortality 
 
All-cause mortality was investigated in studies of MPS (11 studies, 1564 participants) (26-36), 
DSE (five studies, 779 participants) (37-41), and coronary angiography (12 studies, 1839 
participants) (22,26,33,40,42-49) (Fig. 2). One study reported all-cause mortality in relation to 
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exercise ECG (477 participants) (37),  and two studies in relation to a resting ECG (667 
participants) (37,50).  The percentages of patients developing outcomes of interest during the study 
follow up period, according to test type and test result are presented in Table 2. Seven additional 
participants in every 100 (95% CI: -0.03–0.18) with an abnormal MPS test result died compared to 
those with a normal test result. For DSE, 12 additional participants in every 100 (95% CI: 0.06–
0.17) with an abnormal test result died, whilst for coronary angiography an additional 15 
participants in every 100 (95% CI: 0.07–0.24) with an abnormal test died compared to those with a 
normal test. Considering the risk of all-cause mortality, there was weak evidence that the 
prognostic value was better for coronary angiography than MPS (RRR 0.69; 95% CI: 0.49–0.96; 
P=0.03) or DSE (RRR 0.72; 95% CI: 0.50–1.02; P=0.06) (Table 3, SDC Fig. 3). 
 
Cardiovascular Mortality 
 
The ability to predict cardiovascular mortality using MPS (10 studies, 1092 participants) (27,29-
33,51-54), DSE (two studies, 202 participants) (55,56), and coronary angiography (seven studies, 
220 participants) was also evaluated (20,33,42,48,53,54,56) (SDC Fig. 2). For every 100 patients 
with an abnormal test, an additional six (CI -0.02–0.13) tested with MPS, 13 (CI -0.01–0.27) tested 
with DSE and 22 (CI 0.13–0.31) tested by coronary angiography died from cardiovascular disease 
compared to those participants with a normal test. The RR of cardiovascular mortality did not vary 
between studies using coronary angiography versus a non-invasive functional test (RRR MPS 0.89; 
95% CI: 0.38–2.10; P=0.78; DSE 1.09; 95% CI: 0.12–10.05; P=0.93, Table 3, SDC Fig. 4). 
 
Major Adverse Cardiac Events 
 
Nineteen studies (2689 participants) reported major adverse cardiovascular events following a MPS 
(19,24,27,28,30-32,34,35,52,57-65), ten studies (637 participants) following DSE 
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(21,38,41,55,56,62,66-69), and 17 studies (1947 participants) following coronary angiography (20-
24,35,43,48,50,56,60,61,63,64,68,70,71) (Fig. 3). One study (19 participants) reported MACE in 
relation to the results of an exercise ECG(37,62) and following a resting ECG in another one study 
(190 participants) (50). MACE following conventional echocardiography was reported in one study 
(87 participants) (62). For every 100 patients with an abnormal test, an additional 20 (CI 0.11–0.29) 
tested with MPS, 24 (CI 0.10–0.38) tested with DSE and 20 (CI 0.08–0.32) tested by coronary 
angiography experienced MACE compared with those participants with a normal test. The RR of 
MACE did not vary between studies using coronary angiography versus non-invasive tests (RRR 
MPS 1.09; 95% CI: 0.64–1.86; P=0.74; DSE 1.56; 95% CI: 0.71–3.45; P=0.25, Table 3, SDC Fig. 
5). 
 
We observed significant heterogeneity for MPS, DSE and coronary angiography studies 
investigating MACE (P <0.0001, 0.002 and <0.0001 respectively), MPS studies investigating 
cardiovascular mortality (P <0.0001), and MPS and coronary angiography studies investigating all-
cause mortality (P <0.0001 for both). For each cardiac test, studies were stratified according to 
definition of an abnormal test result. Heterogeneity persisted after stratifying studies according to 
definition of an abnormal test result (SDC Table 2).   
 
Sensitivity analysis and investigation of heterogeneity 
 
As test use has changed over time, a sensitivity analysis was performed on studies published from 
2000 onwards, to examine contemporary evidence (Table 4). Overall, although the confidence 
intervals of the summary estimates were wider, due to reduced power from smaller numbers of 
included participants, the point estimates were similar to the overall analysis when all studies were 
included. Heterogeneity largely persisted even in the group of studies published from 2000 
onwards.  
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To evaluate heterogeneity further, we built meta-regression models for each of the specified 
outcomes. The frequency of abnormal cardiac results in the study population, proportion of patients 
transplanted during follow up, prevalence of diabetes mellitus, proportion of the study population 
that was revascularized or transplanted, and median duration of follow-up did not have a significant 
effect on the RR of any of the pre-specified outcomes (Fig. 4). Six studies investigating coronary 
angiography presented separate outcome data according to whether or not study participants 
underwent revascularization (45,46,48,56,63,64). Three studies provided separate data for all-cause 
mortality according to revascularization status (45,46,48). Using logistic regression random effects 
models, after accounting for the effect of revascularization, the odds ratio (OR) for all-cause 
mortality for abnormal coronary angiography was 2.96 (95% CI: 1.25–7.00; P=0.01). Four of these 
studies provided data for MACE (48,56,63,64). The OR for MACE if a patient was found to have 
significant coronary artery disease on coronary angiography was 16.02 (95% CI: 2.42–105.98; 
P=0.004). Revascularization, however, was associated with a significant reduction of future MACE 
(OR 0.19; 95% CI: 0.05–0.72; P=0.01). Revascularization was also associated with a significant 
reduction in risk of all-cause mortality (OR 0.28; 95% CI: 0.12–0.64; P=0.003). 
 
Fourteen studies presented separate outcome data according to transplantation status (27,29-
33,36,45,50,56,57,63,64,70). Transplantation reduced the risk of all-cause mortality (OR 0.19; 95% 
CI: 0.11–0.33; P<0.001) and cardiovascular mortality (OR 0.32; 95% CI: 0.16–0.65; P=0.001), but 
not MACE (OR 0.78; 95% CI: 0.24–2.53; P=0.7). Insufficient studies were available to provide 
separate outcome data according to both transplantation and revascularization status, and therefore 
we were unable to find their adjusted combined effects on adverse outcome. 
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Discussion 
 
This current systematic review presents the largest meta-analysis of prognostic data to date for 
DSE, MPS and coronary angiography in potential kidney transplant recipients. We found that when 
performed as part of preoperative cardiac screening, the prognostic value of an abnormal DSE or 
MPS appeared to be at least as good as abnormal coronary angiography for predicting the outcomes 
cardiovascular mortality and MACE. 
Our review describes more mortality and cardiovascular outcomes than an earlier review published 
in 2003 (72), that focused on MPS, included only twelve studies (with many studies using older 
stress-perfusion protocols) and only investigated the ability of abnormal test results to predict 
cardiovascular mortality and myocardial infarction. This earlier review concluded that abnormal 
MPS was useful in predicting myocardial infarction and cardiac death in patients with ESKD on the 
basis of a statistically significant elevated RR of adverse outcome for an abnormal test result 
compared with a normal test (RR cardiac death 2.52, 95% CI: 1.25–5.08; P=0.01; RR myocardial 
infarction 2.79, 95% CI: 0.85–9.21; P=0.09). We obtained similar results for mortality outcomes 
and MACE for MPS, albeit with greater statistical precision due to the much larger number of 
included studies and participants. Transplantation was associated with improved survival and 
revascularization was associated with less MACE.  
 
For the first time, our study provides clarity on the ability of MPS, DSE and coronary angiography 
at predicting adverse cardiac outcomes. These cardiac tests are the most commonly used and so our 
conclusions provide clinicians robust data in helping decide which test should be used. Our results 
question the rationale of routinely performing either a non-invasive or an invasive cardiac testing 
before a kidney transplant as all tests predict outcomes poorly, since a large number of patients 
with negative test results still have adverse cardiac outcomes, while a substantial proportion of 
patients with abnormal test results do not have adverse cardiac outcome. Unfortunately, the 
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included studies did not elaborate further on the characteristics of the patients who had false 
negative test results, and it is unclear whether this group of patients had a higher incidence of 
valvular heart disease, atrial fibrillation or pulmonary hypertension, which may have put them at 
increased risk of adverse events. We acknowledge that no test is perfect, and, in addition, our data 
does not indicate clear superiority of one non-invasive test over the other. Choice of non-invasive 
testing is often influenced by other factors such as physician preference and presence of 
comorbidities that necessitate one test over the other (e.g. MPS is favoured in patients with 
uncontrolled hypertension or arrhythmia, while DSE is favoured in patients with reversible airways 
disease or hypotension). Furthermore, underlying differences are likely to exist in the baseline 
characteristics among the patient populations that underwent MPS and DSE. 
  
In contrast with the earlier review (72), which found that reversible defects were associated with 
increased risk of cardiac death, we did not find evidence that only reversible defects in MPS or 
regional wall motion abnormalities on DSE were more predictive of adverse cardiac events than 
when defining an abnormal test as both fixed and reversible abnormalities.  Acute myocardial 
ischaemia is not the only cause of adverse cardiac outcome in patients with ESKD as arrhythmias 
and decompensated congestive cardiac failure are also common (9). Peri-operative complications 
occur more frequently in patients with cardiomyopathy and poor left ventricular systolic function 
(6), findings which are common in patients with ESKD and which can be diagnosed with both MPS 
and DSE. This may explain why non-invasive functional tests performed as well as coronary 
angiography in predicting MACE and cardiovascular mortality, and why DSE and MPS studies that 
included fixed abnormalities in their definition of an “abnormal test result” were also able to 
identify patients at increased risk of adverse cardiac outcome.  
 
Cardiovascular complications, sepsis and death from renal failure comprise the major causes of 
death in the short to medium term following kidney transplantation. Interestingly, there was some 
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evidence that coronary angiography was better than MPS or DSE at predicting all-cause mortality 
but equivalent to these non-invasive tests when predicting risk of cardiovascular mortality. This 
finding should be interpreted with caution as it was of only borderline statistical significance and 
because estimates of risk of all-cause and cardiovascular mortality were derived from different 
study populations. 
 
Strengths of this work include a comprehensive search strategy which identified both published and 
unpublished studies. Our results are also specific to candidates for kidney transplantation because 
we only included studies of potential kidney transplant recipients and not unselected patients with 
ESKD. This avoided potential differences in underlying prevalence of coronary artery disease, co-
morbidities and clinical rationale for testing which one might expect in studies which included 
unselected dialysis patients.  
 
Our systematic review had several limitations. The conclusion that the prognostic value of an 
abnormal DSE or MPS appeared to be at least as good as abnormal coronary angiography for 
predicting the outcomes cardiovascular mortality and MACE is based on these tests being 
performed in similar patient populations. The populations described were broadly similar across 
studies, although studies evaluating coronary angiography had higher event rates for each of the 
outcomes of interest compared with studies evaluating non-invasive tests (Table 2). It is therefore 
possible that those undergoing diagnostic coronary angiography may have already had a previous 
abnormal DSE or MPS, or be otherwise at higher risk. It is possible that the predictive ability of 
coronary angiography was falsely reduced by subsequent revascularisation after abnormal coronary 
angiography, as percutaneous coronary interventions or coronary artery bypass surgery may have 
reduced the risk of future adverse cardiac events compared with what would have been expected 
according to the natural history of this condition. In the general population, early revascularization 
can significantly change the natural history of coronary artery disease and affect survival, 
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especially for left main disease, proximal left anterior descending or severe three-vessel coronary 
artery disease. However, it is unclear whether this holds true for patients with ESKD. The optimum 
revascularisation strategy remains unclear in patients with ESKD and obstructive coronary artery 
disease, as percutaneous coronary intervention is associated with improved early survival, while 
coronary artery bypass surgery long term survival (73). In the majority of studies, it is unclear 
whether cardiac events occurred pre- or post-transplant. Few studies presented sufficient data 
regarding which patients in their cohort received early revascularization following cardiac testing 
or the type of revascularization strategy, so we could not control for this during analysis. As a 
result, we were unable to determine whether or not an abnormal test result leading to 
revascularization affects either wait list or post-transplant mortality or MACE. Several studies 
provided data on whether or not participants received a kidney transplant and whether or not 
participants underwent cardiac revascularization but rarely gave data regarding both. We were 
therefore unable to adjust for the competing effects of revascularisation and transplantation. 
Unequal numbers of patients underwent MPS, DSE and coronary angiography, with more 
participants undergoing MPS. The small numbers of participant undergoing DSE may affect the 
precision of our results, as well as the power to detect any significant difference between MPS and 
DSE. Duration of follow up varied within and between studies and made comparison of tests 
difficult. Although we explored the effect of study duration in meta-regression and did not find a 
relationship between median duration of follow up and outcome, this was performed using study-
level data only. An analysis of individual patient level data would potentially allow more subtle 
differences to be revealed. Because we did not have access to individual patient data, we could not 
examine the effect of potential confounders of adverse events after a kidney transplant, including 
the time spent of the transplant waiting list, duration of follow up and whether participants had any 
heart revascularization before or after their kidney transplant. It was not possible to evaluate 
whether prognostic test performance differed according to gender as this was invariably not 
reported in the primary studies identified in this review. A substantial number of studies in this 
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review were unblinded, with physicians caring for the patients having access to the results, and this 
could create significant bias with respect to having imaging results impact on future patient care. 
The studies included in this analysis also spanned three decades. The fact that the sensitivity 
analysis including only studies performed after 2000 yields similar results to the overall analysis is 
reassuring. Nevertheless, test performance, diagnostic accuracy and perioperative management of 
patients with cardiovascular risk may change in the future with technical advances. Despite these 
limitations, we believe our work represents the best pragmatic design and most comprehensive 
overview of the relationship between cardiac test results and subsequent patient outcomes in this 
population. 
 
DSE requires an intravenous infusion and is both time and labour intensive. Although the 
diagnostic accuracy of exercise stress echocardiography, which is more easily accessible, is likely 
similar to that of DSE in the healthy normal population, there is a higher risk of sub-maximal stress 
and uninterpretable test result with exercise stress testing, especially among patients with renal 
impairment who may have exercise limitation due to other comorbidities such as peripheral 
vascular disease, diastolic dysfunction secondary to hypertensive heart disease, fluid overload and 
pulmonary hypertension. DSE has an advantage over MPS in that it does not involve radiation 
exposure, and this should be a consideration for patients being considered for kidney 
transplantation who often require repeated screening investigations due to long waiting lists for 
transplantation and because they are increased risk of future malignant complications. 
 
In conclusion, non-invasive screening tests appear to be at least as good as coronary angiography at 
predicting future adverse outcome. Both normal DSE and MPS results are associated with a 
relatively low risk of future adverse events; a normal non-invasive screening test should therefore 
reassure both the clinician and patient. Initial investigation with coronary angiography, is not 
warranted in the absence of a conventional indication or as part of a research study. Future studies 
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are required to investigate whether or not cardiac evaluation strategies result in lower risk of 
MACE and improved survival. , and which cardiac test should be offered to patients based on their 
baseline cardiovascular risk. Given that some patients with negative test results develop adverse 
cardiac events, further study into the characteristics of patients belonging to this false negative 
cohort should be performed. Better understanding of this patient group and the mechanisms of 
adverse cardiac events in patients with normal non-invasive testing and/or coronary angiography 
may help identify other important preoperative risk factors and potentially reduce the frequency of 
adverse cardiovascular events in the future. 
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Table 1: Characteristics of studies included in the quantitative meta-analysis 
 
Study Country 
Number of 
patients 
undergoing test 
Definition of 
abnormal test 
(% stenosis, type of 
defect, RWMA) 
% patients 
with known 
cardiovascular 
disease  
% 
diabetic 
% study 
population 
revascularized 
% study 
population 
transplanted 
Median 
follow up 
(years) 
Outcomes 
measured 
Myocardial perfusion scintigraphya 
Ali 2011 (4) Qatar 39 Reversible ? 47 1.3 100 5.2 MACE 
Arantes 2010 (1) Brazil 363 Fixed+reversible 30 32 ? 0 1.4 MACE 
Atkinson 2011 (1) UK 47 Fixed+reversible ?  23 8.5 38 6.3 ACM 
Brown 1989 (2) USA 65 Reversible 3 55 ? 54 1.9 MACE 
Camp 1990 (2) USA 40 Reversible 7.5 100 2.5  52.5 0.9 MACE 
Cottier 1990 (6) Switzerland 70 Fixed+reversible 0 0 0 87 2.3 CVM 
Derfler 1991 (2) Austria 23 Fixed+reversible 17 17 ? 100 6 
MACE 
CVM 
ACM 
Feola 2002 (1) Italy 82 Reversible 2  24 6.1 27 2.4 
MACE 
ACM 
Fuster 2000 (1) Spain 77 Reversible 10 100 1.3 94 ? MACE 
Gowdak 2010 (1) Brazil 234 Reversible ? 45 ? ? 2.1 MACE 
Holley 1991 (3) USA 141 Reversible ? 100 0.7 68 3.6 MACE 
Le 1994 (3) USA 95 Reversible 9 60 3.2 43 2.9 
CVM 
ACM 
Leonardi 2009 (1) Italy 302 Reversible 43 6 3.0 55 3.5 
CVM 
ACM 
Lewis 2002 (4) USA 112 Fixed+reversible 10 32 2.7 56 2.3 
MACE 
CVM 
Lin 2001 (5) USA 95 Reversible 17 100 2.1 ? 1.0 MACE 
Marwick 1990 (2) USA 45 Fixed + reversible 16 31 ? ? 2.1 CVM 
Mistry 1990 (2) USA 176 Reversible ? 100 6.8 100 0.02 MACE 
Morrow 1983 (3) USA 54 Reversible 7 100 ? 70 2.5 
MACE 
CVM 
ACM 
Patel 2003 (5) UK 174 Fixed+reversible 5 28 4.6 100 3.5 
MACE  
CVM 
ACM 
Philipson 1986 (3) USA 60 Reversible ? 100 ? 62 1.0 
MACE 
ACM 
Radhakrishnan USA 505 Reversible ? ? 1.4 ? 1.0 MACE 
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2012 
Ruparelia 2011 (5) UK 98 Fixed+reversible NA 100 3.1 100 1.0 MACE 
Stoll 2011 UK 99 Fixed+reversible ? 100 12.1 ? ? 
MACE 
ACM 
Vandenberg 1996 
(4) 
USA 41 Fixed+reversible 0 100 9.8 79 2.9 
MACE 
ACM 
Venkataraman 
2008 (5) 
USA 150 Fixed+reversible NA 66 44.7 0 3.4 ACM 
Wong 2008 (5) UK 126 Reversible 29 42 4.0 33 2.6 CVM 
Dobutamine stress echocardiography 
Bates 1996 USA 53 Any RWMA 23 100 7.5 66 2.2 
MACE 
CVM 
Bergeron 2007 USA 477 Any RWMA 31 49 ? 33 2.3 ACM 
Brennan  1997 USA 47 New RWMA 21 56 2.1 ? 1.7 
MACE 
ACM 
Cortigiani 2004 Italy 71 New RWMA 3 21 4.2 45 3.0 MACE 
Cross 1996 USA 72 ? ? ? 4.2 ? 2.2 MACE 
De Lima 2003 Brazil 93 New RWMA 10 30 ? ? 4.0 MACE 
Herzog 1999 USA 50 New RWMA 16 82 32 44 1.9 MACE 
Krotin 2007 Serbia 24 New RWMA ? ? ? ? ? MACE 
Lin 2001 USA 45 New RWMA 17 100 ? ? 1.0 MACE 
Reis 1995 USA 97 New RWMA 30 64 4.1 26 1.0 ACM 
Sharma 2005 UK 125 New RWMA 13 39 12.0 28 1.6 ACM 
Tita 2008 USA 149 New RWMA 11 65 0.7 100 2.9 
MACE 
CVM 
West 2000 USA 33 Any RWMA ? ? 15.2 ? ? 
MACE 
ACM 
Coronary angiography 
Ali 2004 Ireland 43 ≥70% stenosis 11 13 23.2 100 5.2 MACE 
Atkinson 2011 UK 47 ≥50% stenosis ?  23 8.5 38 6.3 ACM 
Bennett 1978 USA 11 ≥70% stenosis 0 100 ? 45 1.7 
CVM 
ACM 
Braun 1984 USA 100 ≥70% stenosis 9 100 ? 58 1.9 ACM 
De Lima 2003 Brazil 110 ≥70% stenosis 10 30 ? ? 4.0 MACE 
De Lima 2010 Brazil 106 ≥70% stenosis 27 32 ? ? 0.80 MACE 
Enkiri 2010 USA 57 ≥70% stenosis 42 61 8.8 51 1.0 ACM 
Eschertzhuber 2005 Austria 89 ≥50% stenosis 100 ? 17.9 100 ? ACM 
Fossati 2004 Italy 18 ? ? 100 11.1 100 0.05 
MACE  
CVM 
ACM 
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Fuster 2000 Spain 12 ≥70% stenosis 10 100 8.3 94 ? MACE 
Gowdak 2007 CAD Brazil 
301 
 
≥70% stenosis 28 42 ? ? 1.8 MACE 
Gowdak 2007 NDT Brazil 288 ≥70% stenosis 29 40 ? 23 1.8 
MACE 
ACM 
Gowdak 2010 Brazil 479 ≥70% stenosis ? 45 ? ? 2.1 MACE 
Herzog 1999 USA 50 ≥50% stenosis 16 82 32 44 1.9 MACE 
Holley 1991 USA 105 ≥50% stenosis ? 100 ? 68 3.6 MACE 
Kahn 2011 USA 357 ≥70% stenosis 21 41 36.0 100 2.9 ACM 
Kumar 2011 UK 657 ≥70% stenosis 18 47 25.5 43 0.30 ACM 
Manske 1997 USA 198 
≥50% stenosis 
≥75% stenosis 
16 100 16.2 81 3.0 MACE  
Manske 1992  USA 26 ≥75% stenosis 19 100 50 54 1.8 
MACE 
CVM 
Marwick 1990 USA 45 
≥70% stenosis 
≥50% stenosis 
16 31 ? ? 2.1 CVM 
Mistry 1990 USA 42 ≥70% stenosis ? 100 ? 100 0.02 MACE 
Philipson 1986 USA 53 ≥50% stenosis ? 100 ? 62 1.0 
MACE 
ACM 
Ruparelia 2011  UK 98 ≥50% stenosis NA 100 3.1 100 1.0 MACE 
Sharma 2005 UK 125 ≥70% stenosis 13 39 12 28 1.6 ACM 
Tita 2008 USA 12 ≥70% stenosis 11 65 8.3 100 2.9 
MACE 
ACM 
Vandenberg 1996 USA 37 ≥50% stenosis 0 100 9.8 79 2.9 MACE 
Wong 2008 UK 19 ? 29 42 26.3 33 2.6 CVM 
Worthley 2003 Australia 40 ≥70% stenosis 18 78 17.5 43 2.3 ACM 
Exercise ECG          
Bennett 1978 USA 11 New ECG changes 0 100 ? 45 1.7 
CVM 
ACM 
Bergeron 2007 USA 477 New ECG changes 31 49 ? 33 2.3 ACM 
Echocardiography 
Lin 2001 USA 87 Reversible 17 100 ? ? 1.0 MACE 
Resting ECG 
Ali 2004 Ireland 190 
Q waves, ST/T 
changes, 
arrhythmia, LVH 
11 13 5.3 100 5.2 
MACE 
ACM 
Bergeron 2007 USA 477 ST/T changes 31 49 ? 33 2.3 ACM 
Lin 2001 USA 19 ? 17 100 ? ? 1.0 MACE 
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a For MPS, the type of stress protocol used is coded: 1=dipyridamole stress, sestamibi; 2=dipyridamole stress, thallium; 3=exercise stress, thallium; 4=multiple stress agents, 
thallium; 5=multiple stress agents, sestamibi; 6=exercise radionucleotide angiocardiography; RWMA: regional wall motion abnormality; MACE: major adverse cardiac event; 
ACM: all-cause mortality; CVM: cardiovascular mortality. CAD: Coronary artery disease (journal); NDT: Nephrology, dialysis and transplantation (journal).
  Page 33  
Table 2: Percentages of patients developing outcome of interest, stratified by test type and test result 
 
 
Outcome Test % patients with abnormal 
test results who develop 
outcome during follow up  
(per 100 tested, 95% CI) 
% patients with normal 
test results who develop 
outcome during follow 
up  
(per 100 tested, 95% CI) 
% of patients who 
develop outcome during 
follow up from  the total 
number of patients tested  
(per 100 tested, 95% CI) 
All-cause mortality MPS studies 28.0 (14.8, 41.2) 18.2 (11.5, 25.0) 23.4 (15.1, 31.64) 
DSE studies 19.6 (0.08, 39.0) 9.4 (0, 20.6) 12.8 (0, 27.8) 
Coronary angiography studies 33.3 (21.8, 44.7) 13.4 (7.7, 19.0) 22.2 (15.4, 29.0) 
Cardiovascular mortality MPS studies 11.2 (5.4, 17.0) 4.4 (2.0, 6.8) 7.8 (4.8, 10.8) 
DSE studies 16.4 (3.2, 29.7) 4.5 (1.4, 7.6) 6.4 (3.0, 9.7) 
Coronary angiography studies 24.9 (16.2, 33.5) 4.1 (0.3, 7.9) 14.5 (9.3, 19.7) 
Major adverse cardiac event MPS studies 19.0 (12.3, 25.6) 3.9 (2.1, 5.6) 9.7 (6.6, 12.8) 
DSE studies 31.6 (17.7, 45.5) 6.3 (4.2, 8.4) 11.1 (7.6, 14.6) 
Coronary angiography studies 32.2 (19.6, 44.8) 8.5 (4.2, 12.8) 20.7 (13.0, 28.4) 
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Table 3: Summary of results 
  
 Studies 
Risk Difference (95%CI)  
per 100 tested 
Risk Ratio 
(95%CI) 
Relative Risk 
Ratio (95%CI)  
P value Relative  
Risk Ratio 
All-cause mortality      
MPS (all studies) 11 7.0 (-3.0, 18) 1.47 (1.16, 1.88) 0.69 (0.49, 0.96) 0.03 
Reversible defects only 6 1.0 (-6.0, 7.0) 1.22 (0.82, 1.81)   
Fixed+reversible defects 5 14 (-1.0, 29) 1.65 (1.22, 2.25)   
DSE (all studies) 5 12 (6.0, 17) 2.09 (1.12, 3.92) 0.72 (0.50, 1.02) 0.06 
Reversible defects only 3 9.0 (1.0, 17) 4.45 (1.54, 12.90)   
Fixed+reversible defects 2 14 (6.0, 22) 1.48 (1.19-1.84)   
Coronary angiography (all studies) 12 15 (7.0, 24) 2.07 (1.45, 2.95) - - 
Abnormal test defined as ≥50% stenosisa 4 25 (-16, 66) 2.15 (0.92, 5.00)   
Abnormal test defined as ≥70% stenosisa 9 12 (5.0, 19) 1.90 (1.27, 2.85)   
Cardiovascular mortality      
MPS (all studies) 10 6.0 (-2.0, 13) 2.23 (1.38, 3.62) 0.89 (0.38, 2.10)  0.78  
Reversible defects only 5 6.0 (1.0, 11) 2.16 (1.11, 4.22)   
Fixed+reversible defects 5 8.0 (-9.0, 25) 2.26 (0.90, 5.66)   
DSE (all studies) 2 13( -1.0, 27) 4.24 (1.28, 14.09) 1.09 (0.12, 10.05) 0.93 
Reversible defects only 1 12 (-5.0, 29) 3.97 (0.95, 16.67)   
Fixed+reversible defects 1 15 (-10, 40) 4.95 (0.55, 44.40)   
Coronary angiography (all studies) 7 22 (13, 31) 3.00 (1.56, 5.78) - - 
Abnormal test defined as ≥50% stenosisa 3 26 (13, 39) 5.55 (0.73, 42.23)   
Abnormal test defined as ≥70% stenosisa 6 25 (14, 36) 2.45 (1.28, 4.70)   
Major adverse cardiac event      
MPS (all studies)  18 20 (11, 29) 3.64 (2.21, 5.99) 1.09 (0.64, 1.86) 0.74 
Reversible defects only 11 27 (13, 41) 5.64 (2.41, 13.21)   
Fixed+reversible defects 7 12 (1.0, 23) 2.60 (1.75, 3.88)   
DSE (all studies) 10 24 (10, 38) 4.62 (2.74, 7.79) 1.56 (0.71, 3.45) 0.25 
Reversible defects onlyb 7 24 (4.0, 45) 3.91 (1.88, 8.16)   
Fixed+reversible defectsb  2 24 (-9.0, 56) 6.38 (1.76, 23.10)   
Coronary angiography (all studies) 13 20 (8.0, 32) 2.83 (1.82, 4.42) - - 
Abnormal test defined as ≥50% stenosis 4 17 (-9.0, 44) 3.63 (2.09, 6.30)   
Abnormal test defined as ≥70% stenosis 9 25 (12, 38) 2.73 (1.73, 4.30)   
 
a Bennett 1978 and Marwick 1990 reported data for both ≥50% stenosis and ≥70% stenosis test thresholds. Wong 2008 did not report the threshold of stenosis used in the study. 
b Cross 1996 did not report the definition of an abnormal test result. It therefore was excluded from the analysis 
  Page 35  
Table 4: Sensitivity analysis only including studies published from 2000 onwards 
 
 
All-cause mortality 
# 
Studies 
#  
Patients 
RR (95%CI)  
RD (95%CI)  
per 100 tested 
Heterogeneity  
P value (I2) 
P value for 
difference 
MPS (all studies) 7 1496 1.51 (0.99, 2.31) 5.0 (-4.0, 14) 0.29 (19) 
0.04 Reversible defects only 3 925 0.63 (0.24, 1.62) -3.0 (-11, 6.0) 0.75 (0) 
Fixed+reversible defects 4 571 1.78 (1.28, 2.46) 14 (-1.0, 29) 0.62 (0) 
DSE (all studies) 3 812 5.07 (1.25, 20.59) 11 (1.0, 21) 0.90 (0) 
0.66 Reversible defects only 1 112 5.95 (1.21, 29.28) 11 (0, 23) 0.45 (0) 
Fixed+reversible defects 2 700 1.48 (1.19, 1.84) 14 (6.0, 22) 0.54 (0) 
Coronary angiography (all studies) 8 1900 2.13 (1.33, 3.38) 12 (3.0, 21) <0.0001 (80) 
0.81 Abnormal test defined as ≥50% stenosis 2 166 0.81 (0.05, 12.63) 19 (-45, 83) <0.0001 (96) 
Abnormal test defined as ≥70% stenosis 6 1734 2.32 (1.33, 4.07) 11 (4.0, 18) 0.02 (62) 
Cardiovascular mortality 
# 
Studies 
#  
Patients 
RR (95%CI) 
RD (95%CI)  
per 100 tested 
Heterogeneity 
P value (I2) 
P value for 
difference 
MPS (all studies) 4 751 2.99 (0.90, 9.90) 6.0 (-6.0, 18) <0.0001 (90) 
0.46 Reversible defects only 2 299 4.44 (1.27, 15.56) 8.0 (2.0, 13) 0.78 (0) 
Fixed+reversible defects 2 452 1.15 (0.04, 33.28) 5.0 (-23, 37) <0.0001 (95) 
DSE (all studies) 1 158 3.97 (0.95, 16.67) 15 (-10, 40) NA 
NA Reversible defects only 0 0 - - - 
Fixed+reversible defects 1 158 3.97 (0.95, 16.67) 15 (-10, 40) NA 
Coronary angiography (all studies) 3 160 2.97 (1.27, 6.91) 18 (5.0, 31) 0.52 (0) 
NA Abnormal test defined as ≥50% stenosis 0 0 - - - 
Abnormal test defined as ≥70% stenosis 3 160 2.97 (1.27, 6.91) 18 (5.0, 31) 0.52 (0) 
MACE 
# 
Studies 
#  
Patients 
RR (95%CI) 
RD (95%CI)  
per 100 tested 
Heterogeneity  
P value (I) 
P value for 
difference 
MPS (all studies) 11 2058 3.79 (1.84, 7.82) 13 (3.0, 23) <0.0001 (94) 
0.38 Reversible defects only 6 1133 7.11 (1.55, 32.59) 19 (-1.0, 38) <0.0001 (94) 
Fixed+reversible defects 5 925 2.86 (1.54, 5.31) 9 (-2.0, 19) <0.0001 (87) 
DSE (all studies) 6 466 3.97 (1.61, 9.74) 25 (1.0, 48) 0.0004 (78) 
0.91 Reversible defects only 5 431 3.99 (1.46, 10.94) 29 (-3.0, 60) 0.0004 (80) 
Fixed+reversible defects 1 35 3.33 (0.17, 64.33) 10 (-7.0, 27) NA 
Coronary angiography (all studies) 6 739 1.93 (1.45, 2.57) 22 (3.0, 41) <0.01 (67) 
NA Abnormal test defined as ≥50% stenosis 0 0 - - - 
Abnormal test defined as ≥70% stenosis 6 739 1.93 (1.45, 2.57) 22 (3.0, 41) <0.01 (67) 
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Figure Legends 
 
Figure 1 
Identification and inclusion of study reports. 
 
Figure 2 
Risk difference of all-cause mortality after an abnormal test result compared with a normal result. 
 
Figure 3 
Risk difference of MACE after an abnormal test result compared with a normal result.  
 
Figure 4 
The effect of characteristics of the included studies on the relative risk of outcomes: examination of 
sources of heterogeneity using meta-regression analysis. 
 
